The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 78
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_Accruals
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 38
-IssueDate 2023-01-01
-Paragraph 118
-Subparagraph e
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_i&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 55
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_OtherNoncurrentLiabilities
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaboration Agreements, Development Milestone Payment

+ References

No definition available.

+ Details

Name:	sny_CollaborationAgreementsDevelopmentMilestonePayment
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaboration Agreements, Regulatory Milestone Payment

+ References

No definition available.

+ Details

Name:	sny_CollaborationAgreementsRegulatoryMilestonePayment
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaboration Agreements, Upfront Payment

+ References

No definition available.

+ Details

Name:	sny_CollaborationAgreementsUpfrontPayment
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Commitments Related To Milestone Payments For Projects Under Collaboration Agreement

+ References

No definition available.

+ Details

Name:	sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Disclosure of Principal Alliances [Line Items]

+ References

No definition available.

+ Details

Name:	sny_DisclosureOfPrincipalAlliancesLineItems
Namespace Prefix:	sny_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Increase (Decrease) Through Remeasurement, Other Non-Current Liabilities

+ References

No definition available.

+ Details

Name:	sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage Of Development Costs Arising From Commercial Operations

+ References

No definition available.

+ Details

Name:	sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations
Namespace Prefix:	sny_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage Of Net Sales Arising From Commercial Operations

+ References

No definition available.

+ Details

Name:	sny_PercentageOfNetSalesArisingFromCommercialOperations
Namespace Prefix:	sny_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage Of Profits Arising From Commercial Operations

+ References

No definition available.

+ Details

Name:	sny_PercentageOfProfitsArisingFromCommercialOperations
Namespace Prefix:	sny_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_AstraZenecaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_OtherIntangibleAssetsExcludingSoftwareMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_GeographicalAreasAxis=sny_MajorTerritoriesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_GeographicalAreasAxis=sny_OtherTerritoriesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_GeographicalAreasAxis=country_CN
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_SwedishOrphanBiovitrumABMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Principal alliances - Agreements on the commercialization of Beyfortus™ (nirsevimab, previously MEDI8897) in the US (Details) - EUR (€) € in Millions		1 Months Ended			3 Months Ended	9 Months Ended	12 Months Ended
	Apr. 09, 2023	Jul. 31, 2023	Nov. 30, 2022	Mar. 31, 2017	Sep. 30, 2019	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of Principal Alliances [Line Items]
Other non-current liabilities						€ 2,340	€ 2,340	€ 519	€ 291
Antibodies Collaboration agreement \| AstraZeneca
Disclosure of Principal Alliances [Line Items]
Collaboration agreements, upfront payment				€ 120
Collaboration agreements, development milestone payment					€ 30
Collaboration agreements, regulatory milestone payment		€ 65	€ 25
Commitments related to milestone payments for projects under collaboration agreements						375	375
Accruals						25	€ 25
Percentage of development costs arising from commercial operations							50.00%
Antibodies Collaboration agreement \| AstraZeneca \| Other intangible assets excluding software
Disclosure of Principal Alliances [Line Items]
Acquisitions and other increases	€ 1,600
Antibodies Collaboration agreement \| AstraZeneca \| Major territories
Disclosure of Principal Alliances [Line Items]
Percentage of profits arising from commercial operations							50.00%
Antibodies Collaboration agreement \| AstraZeneca \| Other territories
Disclosure of Principal Alliances [Line Items]
Percentage of net sales arising from commercial operations							25.00%
Antibodies Collaboration agreement \| AstraZeneca \| China
Disclosure of Principal Alliances [Line Items]
Percentage of profits arising from commercial operations	50.00%
Antibodies Collaboration agreement \| Swedish Orphan Biovitrum AB
Disclosure of Principal Alliances [Line Items]
Other non-current liabilities	€ 1,600					1,960	€ 1,960
Increase through remeasurement of financial liability						€ 541